Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05883709 | A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL | unknown | — | 15 | Zhao WeiliOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05874778 | A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission | unknown | Phase 2 | 108 | Tianjin Medical University Cancer Institute and HospitalOTHER |
| 0 |
| May 25, 2023 |
| clinicaltrials |
| NCT05179733 | The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years | unknown | Phase 3 | 280 | Ruijin HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05863845 | Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | unknown | N/A | 52 | Ruijin HospitalOTHER | 0 | May 18, 2023 | clinicaltrials |
| NCT05852028 | A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma | unknown | — | 250 | Ruijin HospitalOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT02632396 | Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission | unknown | Phase 1 / Phase 2 | 12 | Emory UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05816746 | Decitabine and Anti-PD-1 in R/R DLBCL | unknown | Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05823701 | Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients | unknown | Phase 2 | 23 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05809180 | Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients | unknown | N/A | 35 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05786989 | Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma | unknown | Phase 4 | 32 | Chongqing University Cancer HospitalOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05784987 | R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | unknown | N/A | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 27, 2023 | clinicaltrials |
| NCT05351346 | Genotype-guided Treatment in DLBCL | unknown | Phase 3 | 1,100 | Ruijin HospitalOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05777369 | R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma | unknown | N/A | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 21, 2023 | clinicaltrials |
| NCT03797170 | Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma | unknown | — | 50 | University of BolognaOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04381741 | CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma(CICPD) | unknown | Phase 1 | 24 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05498259 | Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | unknown | Phase 2 | 46 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT05693519 | GastroIntestinal Cancer in Children and Adolescents(GICCA) | unknown | — | 2,500 | Paul G. Kemps, MDOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT05690191 | Chidamide in Patients With Recurrent and Refractory Diffuse Large b | unknown | — | 169 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT02752815 | Reduced Chemotherapy in Low Risk DLBCL | unknown | Phase 4 | 290 | Ruijin HospitalOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT05479136 | 18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy(DRARCH) | unknown | Phase 3 | 30 | Nicole HillOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05596097 | Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission | unknown | Phase 2 | 15 | LanZhou UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05575973 | Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma | unknown | Phase 2 | 55 | Jianfeng ZhouOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03891355 | Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL(FIL_KLIMT) | unknown | Phase 2 | 16 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05532761 | Multidimensional Assessment of Quality of Life, Social and Professional Life and Care Utilization in Patients With Diffuse Large Cell B-cell Lymphoma Treated With CAR-T Cells(QUALITOP CAR-T) | unknown | — | 30 | Hospices Civils de LyonOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05189782 | Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma | unknown | — | 15 | Ruijin HospitalOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT05498636 | SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression | unknown | Phase 1 / Phase 2 | 67 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05504603 | Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma | unknown | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT04226937 | DLBCL Interim Response Evaluation for Customised Therapy(DIRECT) | unknown | — | 150 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05486013 | Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma | unknown | — | 30 | Peking University Third HospitalOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT03736616 | Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL | unknown | Phase 2 | 47 | Swedish Medical CenterOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT05444322 | A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | unknown | Early Phase 1 | 18 | He HuangOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT05381506 | Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma(O-Gemox) | unknown | Phase 2 | 77 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT05428670 | The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma. | unknown | Phase 2 | 150 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT05429918 | Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years | unknown | — | 60 | Peking University Third HospitalOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT05414162 | Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy | unknown | — | 60 | University Hospital, BonnOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05406154 | Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years | unknown | — | 60 | Peking University Third HospitalOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT03971305 | A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL | unknown | — | 300 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT04058470 | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 140 | Huiqiang HuangOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05093140 | Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL(CREDIT) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 0 | Apr 7, 2022 | clinicaltrials |
| NCT05287984 | Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL(ZFCR/ZBR) | unknown | Phase 2 | 63 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05003141 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | unknown | Phase 1 | 110 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics)INDUSTRY | 3 | Mar 28, 2022 | clinicaltrials |
| NCT04112238 | ctDNA and Metabolites in CSF as Early Biomarkers of Secondary CNS Involvement in Diffuse Large B-cell Lymphoma(CNSctDNA) | unknown | — | 75 | Herlev HospitalOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05290337 | ZR-CHOP in DLBCL With Specific Gene Abnormality | unknown | Phase 2 | 62 | Fudan UniversityOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05200312 | A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma(ZR2-CHOP) | unknown | Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT05269914 | Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL | unknown | N/A | 10 | The Affiliated Hospital of Qingdao UniversityOTHER | 0 | Mar 8, 2022 | clinicaltrials |
| NCT02481310 | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT03837873 | DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma | unknown | Phase 2 | 118 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05208853 | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma | unknown | Early Phase 1 | 9 | Zhejiang UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT03629873 | Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects | unknown | Phase 2 | 69 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05164770 | Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | unknown | Phase 3 | 160 | Shandong Provincial HospitalOTHER_GOV | 1 | Dec 21, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Jun 1, 2023source: clinicaltrials